The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189.
Jack Henry & Associates
JKHY · a US exchange · USD · Market cap $12.2B · 7,300 employees
Jack Henry & Associates, Inc.
FAIL · Does not pass the screenPrice as of 13 Nov 2026Daily close, not a live quoteLast reviewed 4 days ago
Screened 2026-11-13 · the tape above runs as of 07:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price177.67 USD at the 13 Nov 2026 close
- Our value readOvervalued vs our fair value, as of 13 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 1.02)
- Last reviewed13 Nov 2026 (4 days ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $151.20 to $181.81, base estimate $158.09 (screen dated 2026-11-13).
- Trend Markup
- Insiders no filings inside 60 days, left as found
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 1.02, read 2026-11-14
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Jack Henry & Associates holds its Markup at $177.67. The statistical read favours the sellers, held for 1 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 1 days |
| Price at the screen | $177.67 |
| Valuation | 24.16 trailing · 21.99 forward price to earnings |
| Values screen | FAIL · score 10.0 |
| Beta | 0.54 |
Five Screens, Shown in Full
Does not pass. Business activity screen
| Test | Figure | Limit | What it means | Status |
|---|---|---|---|---|
| Business activity | Excluded | Core business clean | Business activity: Financials sector | Fail |
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical ReadWhy It Falls Short, in Plain English
Jack Henry & Associates does not clear the screen at the business-activity stage. It operates in conventional financial services, which the screen treats as interest-based, so the financial ratios are not the deciding factor here.
Read as at 2026-11-15. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when JKHY's ethical verdict changes
Today JKHY does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Overvalued vs our fair value, as of 13 Nov 2026: it trades above our $158.09 fair value estimate, strong competitive moat, 8.80% revenue growth.
How a fair value is estimated: discounted cash flow (DCF).
Fair value range in USD, drawn from the 2026-11-13 screen. The gold marker is the market price at the same screen. The price runs 12.4% above the base estimate.
Third-party analyst targets: 19 covering, consensus Buy. The average target sits +11% from the screen price.
Reading the gap · Our more conservative model reads it as fully-to-richly valued here, while the Street is more bullish: a quality-at-a-fair-price name rather than a deep-value one.
Price History & ProjectionsWhere our models see it going: fair-value estimate $158.09, with a range of $151.20 to $181.81, dated to the 2026-11-13 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain WordsJack Henry powers bank systems yet fails ethically
Jack Henry keeps the back-office systems running for thousands of smaller banks every day. The numbers show a strong moat, 25% returns on equity, 21% profit margins and 9% revenue growth, yet we pass because the ethical screen flags the business outright.
Forward earnings sit at 21.4 times while the shares trade 6% above our fair value of 142.03. Fourteen analysts still lean buy with a median target near 184, but none of that overrides the screen result.
Any regulatory tightening on payment flows or loss of a few large clients could hit growth fast. Analysis, not advice.
| Forward P/E | 22.0xexpensive even after accounting for its growth |
| Trailing P/E | 24.2xa premium valuation |
| EPS, trailing | 7.28 |
| EPS, forward | 8.00 |
| Revenue growth | +8.8%steady growth |
| Profit margin | 20.0%healthy profit margins |
| Return on equity | 24.3%an exceptional return on shareholder capital |
| FCF yield | 3.30% |
| Dividend yield | 1.70% |
| Debt to equity | 0.06minimal debt: a conservative balance sheet |
| Current ratio | 1.38adequate liquidity, worth monitoring |
| Beta | 0.54steadier than the market |
| Short interest, float | 0.07% |
| 52-week range | 121.04 - 193.39 |
| Moat | STRONG |
| Market cap | $12.2B |
| Employees | 7,300 |
Another profit measure, before interest, tax and non-cash costs: EBITDA.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to TradeJKHY trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
Every Entry, As Written
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.7% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 6.1% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The analysis reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from distribution to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 2.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is sitting below its long-term trend line with momentum reading bullish. Over the past year the shares are down 28%. Our forward projection puts the odds of a 10% gain over the next month near 9%. The street (14 analysts) rates it buy, with a mean price target of $189.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
- Jack Henry Named One of America's Top 100 Most Loved Workplaces® for 2026 Yahoo Finance · 8d ago
- 3 Cash Management Software Stocks Worth Watching As Liquidity Moves Back Into Focus Yahoo Finance · 10d ago
- Jack Henry CFO Mimi Carsley to Present at Upcoming Investor Conferences Yahoo Finance · 11d ago
- Jack Henry & Associates Needs to Show Clearer Upside to Growth Targets, Morgan Stanley Says Yahoo Finance · 12d ago
- JKHY Q1 Earnings Beat Estimates on Cloud & Payments Growth Yahoo Finance · 12d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-05-14 | ADELSON GREGORY R. | Chief Executive Officer | 2,000 | $266,840 | |
| 2026-05-14 | CARSLEY MIMI | Chief Financial Officer | 375 | $50,295 | |
| 2026-02-12 | FLANIGAN MATTHEW C | Director | 440 | · | |
| 2025-12-31 | MCLACHLAN SHANON G. | Chief Operating Officer | 183 | · | |
| 2025-12-15 | SWEARINGEN RENEE ANN | Officer | 200 | · | |
| 2025-12-01 | FOSS DAVID B | Director | 20,000 | $3,498,400 | |
| 2025-11-11 | FLANIGAN MATTHEW C | Director | 1,159 | · | |
| 2025-11-11 | BROWN WESLEY A | Director | 1,159 | · | |
| 2025-11-11 | WILSON THOMAS HAMPTON JR. | Director | 1,159 | · | |
| 2025-11-11 | WIMSETT THOMAS A | Director | 1,159 | · |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-06-16 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2024-05-03 | Tommy Tuberville | Republican | sell | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $143.01 | -10.7% | $0.61 | $898 | -10.2% |
| 2 months | $146.54 | -12.8% | $0.61 | $876 | -12.4% |
| 3 months | $165.60 | -22.9% | $0.61 | $775 | -22.5% |
| 6 months | $185.67 | -31.2% | $1.22 | $695 | -30.5% |
| 1 year | $176.83 | -27.8% | $2.38 | $736 | -26.4% |
| 2 years | $159.55 | -19.9% | $4.64 | $830 | -17.0% |
| 3 years | $151.55 | -15.7% | $6.78 | $888 | -11.2% |
| 5 years | $152.50 | -16.2% | $10.70 | $908 | -9.2% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever JKHY does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.